E-LIB Suche - Ergebnisse für: Kallmann, Boris-Alexander

1

TAURUS-MS II: real-world use of teriflunomide in Germany an..:

Kallmann, Boris-Alexander ; zu Eulenburg, Georg ; Kullmann, Jennifer S..
Therapeutic Advances in Neurological Disorders. 17 (2024) - p. , 2024

Link: https://doi.org/10.1177/..

2

Association of health behaviour and clinical manifestation ..:

Krause, Nicole ; Derad, Carlotta ; von Glasenapp, Barbara...
Multiple Sclerosis and Related Disorders. 79 (2023) - p. 105043 , 2023

Link: https://doi.org/10.1016/..

3

Disseminated necrotizing leukoencephalopathy eight months a..:

Metz, Imke ; Rieckmann, Peter ; Kallmann, Boris-Alexander.
Acta Neuropathologica Communications. 4 (2016) 1 - p. , 2016

Link: https://doi.org/10.1186/..

4

Disseminated necrotizing leukoencephalopathy eight months a..:

Metz, Imke ; Rieckmann, Peter ; Kallmann, Boris-Alexander.
https://resolver.sub.uni-goettingen.de/purl?gro-2/58763. , 2016

Link: https://resolver.sub.uni..

5

Determination of ventricular diameters in multiple sclerosi..:

Kallmann, Boris-A. ; Sauer, Judith ; Schließer, Mira...
Journal of Neurology. 251 (2004) 1 - p. 30-34 , 2004

Link: https://doi.org/10.1007/..

6

Characteristic gene expression profile of primary human cer..:

Kallmann, Boris-A. ; Wagner, Sven ; Hummel, Vera...
The FASEB Journal. 16 (2002) 6 - p. 589-591 , 2002

Link: https://doi.org/10.1096/..

7

Exogenous nitric oxide modulates cytokine production in hum..:

Kallmann, Boris-A. ; Malzkorn, Rene ; Kolb, Hubert
Life Sciences. 65 (1999) 17 - p. 1787-1794 , 1999

Link: https://doi.org/10.1016/..

8

REBISTART: Adherence of Patients with Multiple Sclerosis to..:

Schwab, Matthias ; Chan, Andrew ; Eser, Anna-Katharina...
Neurology and Therapy. 13 (2024) 3 - p. 641-653 , 2024

Link: https://doi.org/10.1007/..

9

Ambulante spezialfachärztliche Versorgung (ASV) für die mul..:

Mäurer, Mathias ; Meier, Uwe ; Wattjes, Mike P....
DGNeurologie. 6 (2023) 6 - p. 481-492 , 2023

Link: https://doi.org/10.1007/..

10

Long-term management of multiple sclerosis patients treated..:

Meuth, Sven G ; Bayas, Antonios ; Kallmann, Boris...
Expert Opinion on Pharmacotherapy. 23 (2022) 13 - p. 1503-1510 , 2022

Link: https://doi.org/10.1080/..

11

Multiple sclerosis therapy consensus group (MSTCG): answers..:

Wiendl, Heinz ; Gold, Ralf ; Zipp, Frauke...
Neurological Research and Practice. 3 (2021) 1 - p. , 2021

Link: https://doi.org/10.1186/..

12

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positi..:

Wiendl, Heinz ; Gold, Ralf ; Berger, Thomas...
Der Nervenarzt. 92 (2021) 8 - p. 773-801 , 2021

Link: https://doi.org/10.1007/..

13

Teriflunomide in relapsing-remitting multiple sclerosis: ou..:

Kallmann, Boris A. ; Ries, Stefan ; Kullmann, Jennifer S....
Therapeutic Advances in Neurological Disorders. 14 (2021) - p. 175628642110055 , 2021

Link: https://doi.org/10.1177/..

14

Multiple Sclerosis Therapy Consensus Group (MSTCG): positio..:

Wiendl, Heinz ; Gold, Ralf ; Berger, Thomas...
Therapeutic Advances in Neurological Disorders. 14 (2021) - p. 175628642110396 , 2021

Link: https://doi.org/10.1177/..

15

Clinical outcomes and treatment satisfaction in patients sw..:

Freedman, Mark S. ; Kallmann, Boris A. ; Meca-Lallana, Jose E....
Neurology. 94 (2020) 15_supplement - p. , 2020

Link: https://doi.org/10.1212/..